Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00676650 · ClinicalTrials.gov registry record · Phase 3
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 873
- Enrollment target
NCT00676650 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 873 participants.
The verdict
NCT00676650, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 873 participants
- Enrollment target
Study Summary
This study will compare the safety and efficacy of sunitinib in combination with prednisone versus placebo and prednisone in patients that have metastatic castration-resistant prostate cancer that has progressed after treatment with a docetaxel-containing chemotherapy regimen. This is a second-line study.
Interventions
- DRUG Placebo
- DRUG Prednisone
- DRUG sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 873 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00676650
The ClinicalTrials.gov registry entry for NCT00676650 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 873 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00676650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00676650 about?
NCT00676650 is a clinical study titled "Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy". This study will compare the safety and efficacy of sunitinib in combination with prednisone versus placebo and prednisone in patients that have metastatic castration-resistant prostate cancer that has progressed after treatment with a docetaxel-containing chemotherapy regimen. This is a second-line ...
What is the current status of trial NCT00676650?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 873 participants. The study started on 2008-07. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00676650?
The interventions under investigation include: Placebo (DRUG), Prednisone (DRUG), sunitinib (DRUG).
Who is sponsoring clinical trial NCT00676650?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.